Journal of the American Academy of Dermatology
Volume 61, Issue 5 , Pages 793-798 , November 2009

Randomized, double-blind, placebo-controlled evaluation of the efficacy of oral psoralen plus ultraviolet A for the treatment of plaque-type psoriasis using the Psoriasis Area Severity Index score (improvement of 75% or greater) at 12 weeks

  • S. Priya Sivanesan, MD, MPH

      Affiliations

    • Department of Dermatology, Pittsburgh University, Pittsburgh, Pennsylvania
    • ,
  • Shilpa Gattu, BS

      Affiliations

    • University of California, Irvine, California
    • ,
  • Judith Hong, MD

      Affiliations

    • Department of Dermatology, University of California, San Francisco, California
    • ,
  • Arianne Chavez-Frazier, MD

      Affiliations

    • Department of Dermatology, University of Texas Health Science Center, Houston, Texas
    • ,
  • Grace D. Bandow, MD

      Affiliations

    • Albert Einstein College of Medicine, New York, New York
    • ,
  • Farah Malick, MD

      Affiliations

    • Department of Dermatology, Wayne State University, Dearborn, Michigan
    • ,
  • Greg Kricorian, MD

      Affiliations

    • Amgen Pharmaceuticals, Orange County, California
    • ,
  • John Koo, MD

      Affiliations

    • Department of Dermatology, University of California, San Francisco, California
    • Corresponding Author InformationReprint requests: John Koo, MD, 515 Spruce St, San Francisco, CA 94118.

,Accepted 22 April 2009.

References 

  1. Lauharanta J. Photochemotherapy. Clin Dermatol. 1997;15:769–780
  2. Frappaz A, Thivolet J. Calcipotriol in combination with PUVA: a randomized double blind placebo study in severe psoriasis. Eur J Dermatol. 1993;3:351–354
  3. Parrish JA, Fitzpatrick TB, Tanenbaum L, Pathak MA. Photochemotherapy of psoriasis with oral methoxsalen and longwave ultraviolet light. N Engl J Med. 1974;291:1207–1211
  4. Melski JW, Tanenbaum L, Parrish JA, Fitzpatrick TB, Bleich HL. Oral methoxsalen photochemotherapy for the treatment of psoriasis: a cooperative clinical trial. J Invest Dermatol. 1977;68:328–335
  5. Wolff K, Fitzpatrick TB, Parrish JA, Gschnait F, Gilchrest B, Honigsmann H, et al. Photochemotherapy for psoriasis with orally administered methoxsalen. Arch Dermatol. 1976;112:943–950
  6. Van Weelden H, Baart de la Faille H, Young E, van der Leun JC. Comparison of narrow-band UV-B phototherapy and PUVA photochemotherapy in the treatment of psoriasis. Acta Derm Venereol. 1990;70:212–215
  7. Gordon PM, Diffey BL, Matthews JN, Farr PM. A randomized comparison of narrow-band TL-01 phototherapy and PUVA photochemotherapy for psoriasis. J Am Acad Dermatol. 1999;41:728–732
  8. Yones SS, Palmer RA, Garibaldinos TT, Hawk JL. Randomized double-blind trial of the treatment of chronic plaque psoriasis: efficacy of psoralen-UV-A therapy vs narrowband UV-B therapy. Arch Dermatol. 2006;142:836–841
  9. Reich K, Nestle FO, Papp K, Ortonne JP, Evans R, Guzzo C, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicenter, double-blind trial. Lancet. 2005;366:1367–1374
  10. Koo J. A randomized, double-blind study comparing the efficacy, safety and optimal dose of two formulations of cyclosporine, Neoral and Sandimmune, in patients with severe psoriasis. Br J Dermatol. 1998;139:88–95
  11. Calzavara-Pinton PG, Carlino A, Manfredi E, Semararo F, Zane C, De Panfilis G. Ocular side effects of PUVA-treated patients refusing eye sun protection. Acta Derm Venereol. 1994;186:164–165
  12. Stern RS. The risk of melanoma in association with long-term exposure to PUVA. J Am Acad Dermatol. 2001;44:755–761
  13. Lindelof B, Sigurgeirsson B, Tegner E, Larko O, Johannesson A, Berne B, et al. PUVA and cancer risk: the Swedish follow-up study. Br J Dermatol. 1999;141:108–112
  14. Koo JYM, Fitzpatrick TB, Krueger G, Lebwohl M, Menter A, Taylor JR. PUVA phototherapy: assessing and optimizing the risk/benefit ratio. Skin Allergy News Suppl. 2001;32:1–15
  15. Stern RS, Lange R. Non-melanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment. J Invest Dermatol. 1988;91:120–124
  16. Stern RS, Liebman EJ, Vakeva L. Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of non melanoma skin cancer: PUVA follow-up study. J Natl Cancer Inst. 1998;90:1278–1284
  17. Stern RS, Lunder EJ. Risk of squamous cell carcinoma and methoxsalen (psoralen and UVA radiation [PUVA]), a meta analysis. Arch Dermatol. 1998;134:1582–1585
  18. Murase JE, Lee EE, Koo J. Effect of ethnicity on the risk of developing nonmelanoma skin cancer following long-term PUVA therapy. Int J Dermatol. 2005;44:1016–1021

 Supported by Valeant Pharmaceuticals.

 Disclosure: Dr Koo has been a clinical researcher and/or consultant and/or speaker for Valeant, Allergan, Warner-Chilcott, Amgen, Biogen, Bristol-Myers Squibb, Centacor, Connetics, Elan, Astellas, Galderma, Genentech, GlaxoSmithKlein, Novartis, Roche, and Serono. Ms Gattu is a consultant for Coria Labs. Dr Kricorian was an employee at Amgen Pharmaceuticals. Drs Sivanesan, Hong, Chavez-Frazier, Bandow, and Malick have no conflicts of interest to declare.

 Interim data were presented orally at the American Academy of Dermatology 63rd Annual Meeting, New Orleans, LA, February 18-22, 2005.

PII: S0190-9622(09)00533-7

doi: 10.1016/j.jaad.2009.04.053

Journal of the American Academy of Dermatology
Volume 61, Issue 5 , Pages 793-798 , November 2009

Article Tools

* Image Usage & Resolution